strategic alternatives
OraSure Misses COVID-19 Antigen Test Sales Guidance; Announces CEO Departure, Strategic Review
OraSure expects to miss its full-year rapid COVID-19 antigen test sales estimate by $10 million, and will now undertake a strategic review.
Fluidigm Q3 Revenues Drop 29 Percent on Supply Chain Issues, Waning COVID-19 Testing
The company also lowered its full-year financial guidance and said its board of directors is undertaking a strategic review to maximize shareholder value.
Admera Health Seeks to Divest Pharmacogenomics, Clinical Services Business
The company will continue to offer research services for biopharma customers but is hoping a strategic partner can take over its clinical portfolio.
Qiagen Completes Strategic Review, Rejects Acquisition Offers
The firm had received interest from unnamed potential acquisition partners following the departure of its CEO, but it has decided to remain as a standalone business.
Curetis Hires Strategic Advisor, Delays Release of Financial Results
The company is delaying the publication of its business and financial update for the first half of 2019 to allow for an ongoing review by its auditors.